Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

GE Healthcare to Be Sole Distributor of Gyros' Nanoliter-Scale Immunoassay Platform in Japan

By BiotechDaily International staff writers
Posted on 20 Jul 2011
GE Healthcare Life Sciences (Little Chalfont, UK), a global provider of transformational medical technologies and services, has signed a sole distribution agreement with Gyros AB (Uppsala, Sweden), a developer of microfluidic technologies to miniaturize and automate immunoassays. Under the agreement, GE Healthcare becomes the sole distributor of the Gyros nanoliter-scale immunoassay platform in Japan.

Major biopharmaceutical companies and their service providers use the Gyros platform worldwide to improve productivity and efficiency when developing biotherapeutics and vaccines, generating time-critical workflows to meet regulatory demands.

Erik Walldén, CEO at Gyros, said, “The growing acceptance of our nanoliter-scale immunoassay platform within the global biopharmaceutical industry makes it imperative that we are represented within the Japanese market. We believe that this agreement with GE Healthcare Life Sciences will be a key factor in our success. As well as the clear commercial synergy between our product portfolios, we can be sure of providing the highest standards of service and support for our Japanese customers. We look forward to a highly successful collaboration.”

Hiroko Watanabe, general manager GE Healthcare Life Sciences, Japan, added, “We are delighted to have signed this agreement with Gyros which will help us expand our offering of value-added and innovative technologies to the biopharmaceutical industry in Japan. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry.”

Related Links:

GE Healthcare Life Sciences
Gyros



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: Neurons (greenish yellow) attach to silk-based scaffold (blue) creating functional networks throughout the scaffold pores (dark areas) (Photo courtesy of Tufts University).

Functional 3D Brain-Like Tissue Model Bioengineered

Researchers recently reported on the development of the first complex, three-dimensional (3D) model comprised of brain-like cortical tissue that displays biochemical and electrophysiologic responses, and... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.